DK2861582T3 - A process for preparing hydroxylated compounds cyclopentylpyrimidin - Google Patents

A process for preparing hydroxylated compounds cyclopentylpyrimidin Download PDF

Info

Publication number
DK2861582T3
DK2861582T3 DK13725042.9T DK13725042T DK2861582T3 DK 2861582 T3 DK2861582 T3 DK 2861582T3 DK 13725042 T DK13725042 T DK 13725042T DK 2861582 T3 DK2861582 T3 DK 2861582T3
Authority
DK
Denmark
Prior art keywords
substituted
unsubstituted
compound
alkyl
salt
Prior art date
Application number
DK13725042.9T
Other languages
Danish (da)
English (en)
Inventor
David Askin
Chong Han
Jonathan W Lane
Travis Remarchuk
Sagar Shakya
C Gregory Sowell
Keith L Spencer
Peter J Stengel
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Application granted granted Critical
Publication of DK2861582T3 publication Critical patent/DK2861582T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DK13725042.9T 2012-05-17 2013-05-17 A process for preparing hydroxylated compounds cyclopentylpyrimidin DK2861582T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648473P 2012-05-17 2012-05-17
US201361785122P 2013-03-14 2013-03-14
PCT/US2013/041666 WO2013173768A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (1)

Publication Number Publication Date
DK2861582T3 true DK2861582T3 (en) 2016-08-22

Family

ID=48485537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13725042.9T DK2861582T3 (en) 2012-05-17 2013-05-17 A process for preparing hydroxylated compounds cyclopentylpyrimidin

Country Status (20)

Country Link
US (4) US9416110B2 (enExample)
EP (1) EP2861582B1 (enExample)
JP (1) JP6284928B2 (enExample)
KR (1) KR102067850B1 (enExample)
CN (1) CN104470913B (enExample)
AU (1) AU2013262505B2 (enExample)
BR (1) BR112014028589B1 (enExample)
CA (1) CA2873654C (enExample)
DK (1) DK2861582T3 (enExample)
ES (1) ES2582557T3 (enExample)
IL (1) IL235715A (enExample)
MX (1) MX353384B (enExample)
MY (1) MY169028A (enExample)
NZ (1) NZ702935A (enExample)
PL (1) PL2861582T3 (enExample)
RU (1) RU2643811C2 (enExample)
SG (1) SG11201407616TA (enExample)
SI (1) SI2861582T1 (enExample)
WO (1) WO2013173768A1 (enExample)
ZA (1) ZA201409261B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2858989T3 (da) 2012-05-17 2020-06-02 Genentech Inc Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil
KR102123131B1 (ko) 2012-05-17 2020-06-15 제넨테크, 인크. 하이드록실화 사이클로펜타피리미딘 화합물 및 이의 염의 제조 방법
DK2861582T3 (en) 2012-05-17 2016-08-22 Array Biopharma Inc A process for preparing hydroxylated compounds cyclopentylpyrimidin
JP6214636B2 (ja) 2012-05-17 2017-10-18 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
HRP20231100T1 (hr) 2013-11-15 2023-12-22 F. Hoffmann - La Roche Ag Postupci za proizvodnju pirimidinilciklopentan spojeva
SG10201806450SA (en) * 2014-09-26 2018-09-27 Hoffmann La Roche PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
CA3032233C (en) 2016-08-10 2021-09-14 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising akt protein kinase inhibitors
CA3175354A1 (en) * 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Process for making hydroxylated cyclopentylpyrimidine compounds
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178829A1 (en) 1993-12-12 1995-06-15 Yigal Cohen A novel method to protect plants from fungal infection
EP0973396A4 (en) 1997-04-07 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU766079B2 (en) 1999-06-03 2003-10-09 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
WO2004108673A2 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
AU2010310786B2 (en) * 2009-10-23 2014-03-27 Eli Lilly And Company AKT inhibitors
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
CN104520263B (zh) 2012-05-17 2016-11-09 基因泰克公司 制备氨基酸化合物的方法
DK2858989T3 (da) 2012-05-17 2020-06-02 Genentech Inc Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil
DK2861582T3 (en) 2012-05-17 2016-08-22 Array Biopharma Inc A process for preparing hydroxylated compounds cyclopentylpyrimidin
JP6214636B2 (ja) 2012-05-17 2017-10-18 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
KR102123131B1 (ko) 2012-05-17 2020-06-15 제넨테크, 인크. 하이드록실화 사이클로펜타피리미딘 화합물 및 이의 염의 제조 방법
CA2889855A1 (en) 2012-11-01 2014-05-08 Robert S. Katz Methods for treating fibromyalgia
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
US10131637B2 (en) 2013-03-15 2018-11-20 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
CN104470913B (zh) 2018-07-20
RU2014151050A (ru) 2016-07-10
JP6284928B2 (ja) 2018-02-28
EP2861582B1 (en) 2016-05-25
US20180258054A1 (en) 2018-09-13
US20170247337A1 (en) 2017-08-31
BR112014028589B1 (pt) 2022-08-23
JP2015517532A (ja) 2015-06-22
US20160318877A1 (en) 2016-11-03
MY169028A (en) 2019-02-04
HK1208451A1 (en) 2016-03-04
AU2013262505A1 (en) 2015-01-22
KR20150020214A (ko) 2015-02-25
CN104470913A (zh) 2015-03-25
US9676730B2 (en) 2017-06-13
CA2873654A1 (en) 2013-11-21
KR102067850B1 (ko) 2020-01-17
MX2014013862A (es) 2015-05-07
CA2873654C (en) 2021-06-22
MX353384B (es) 2018-01-10
SG11201407616TA (en) 2015-03-30
US20150152067A1 (en) 2015-06-04
IL235715A (en) 2017-02-28
ES2582557T3 (es) 2016-09-13
EP2861582A1 (en) 2015-04-22
PL2861582T3 (pl) 2016-11-30
WO2013173768A1 (en) 2013-11-21
AU2013262505B2 (en) 2017-09-21
BR112014028589A2 (pt) 2017-07-25
US9416110B2 (en) 2016-08-16
SI2861582T1 (sl) 2016-09-30
RU2643811C2 (ru) 2018-02-06
IL235715A0 (en) 2015-02-01
NZ702935A (en) 2017-02-24
US9790190B2 (en) 2017-10-17
ZA201409261B (en) 2017-05-31

Similar Documents

Publication Publication Date Title
AU2013262505B2 (en) Process for making hydroxylated cyclopentylpyrimidine compounds
JP2024524851A (ja) Erk阻害剤を調製するプロセス
AU2019253849B2 (en) Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
EP2850054B1 (en) Process for making amino acid compounds
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208451B (zh) 用於製造羥基化的環戊基嘧啶化合物的方法